Skip to main content
SpringerLink
Log in

The Role of Intensity-Modulated Radiotherapy to Optimize Outcomes in Locally Advanced Rectal Cancer

  • Localized Colorectal Cancer (R Glynne-Jones, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Intensity-modulated radiation therapy (IMRT) as neoadjuvant treatment of locally advanced rectal cancer (LARC) patients has been explored by some authors since 2006. Dosimetrical analyses and clinical outcomes have been published in recent years. Although there are encouraging dosimetrical results, there are no solid clinical data supporting the routine use of IMRT for preoperative treatment of LARC patients. In this article, we analyze the published dosimetrical and clinical data and current evidence for the use of IMRT in LARC patients. We hypothesize the role of IMRT to treat rectal cancer patients in the current technological age. The small bowel dose reduction that could lead to a reduction in GI toxicity and encourage higher rates of compliance, the potential dose escalation to the target volume, and the integration with higher doses of chemotherapy and its potential implications to optimize clinical outcomes in terms of toxicity and efficacy are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Sauer R, Fietkau R, Wittekind C, et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis. 2003;5(5):406–15.

    Article  CAS  PubMed  Google Scholar 

  2. Rodel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87. Randomized study evaluating the efficacy of adding oxaliplatin to standard treatment.

    Article  PubMed  Google Scholar 

  3. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558–65.

    Article  CAS  PubMed  Google Scholar 

  4. Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25(7):1356–62.

    Article  CAS  PubMed  Google Scholar 

  5. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33. Long-term results of randomized study that confirm that there is a persisting significant improvement of pre- versus postoperative CRT on local control.

    Article  CAS  PubMed  Google Scholar 

  6. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol, Biol, Phys. 2002;52(1):176–83.

    Article  Google Scholar 

  7. Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol, Biol, Phys. 2006;66(2):505–13.

    Article  Google Scholar 

  8. Eisbruch A. Intensity-modulated radiation therapy: a clinical perspective. Introduction. Semin Radiat Oncol. 2002;12(3):197–8.

    Article  PubMed  Google Scholar 

  9. Sebag-Montefiore D, Bujko K, Valentini V. Rectal cancer multidisciplinary management: evidences and future landscape. Radiother Oncol. 2009;92(2):145–7.

    Article  PubMed  Google Scholar 

  10. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241(5):829–36. discussion 836-8.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Valentini V, Coco C, Picciocchi A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol, Biol, Phys. 2002;53(3):664–74.

    Article  Google Scholar 

  12. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688–96.

    Article  PubMed  Google Scholar 

  13. Guerrero Urbano MT, Henrys AJ, Adams EJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol, Biol, Phys. 2006;65(3):907–16.

    Article  Google Scholar 

  14. Callister MD, Ezzell GA, Gunderson LL. 2143: IMRT reduces the dose to small bowel and other pelvic organs in the preoperative treatment of rectal cancer. Int J Radiat Oncol*Biol*Phys. 2006;66(3, Supplement):S290.

    Article  Google Scholar 

  15. Arbea L, Ramos LI, Martinez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:17–717X-5-17.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Engels B, De Ridder M, Tournel K, et al. Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel. Int J Radiat Oncol, Biol, Phys. 2009;74(5):1476–80.

    Article  Google Scholar 

  17. Mok H, Crane CH, Palmer MB, et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol. 2011;6:63–717X-6-63.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Ballonoff A, Kavanagh B, McCarter M, et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008;31(3):264–70.

    Article  CAS  PubMed  Google Scholar 

  19. Engels B, Tournel K, Everaert H, et al. Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer. Int J Radiat Oncol, Biol, Phys. 2012;83(1):142–8.

    Article  Google Scholar 

  20. Arbea L, Martinez-Monge R, Diaz-Gonzalez JA, et al. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and Oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Int J Radiat Oncol, Biol, Phys. 2012;83(2):587–93.

    Article  CAS  Google Scholar 

  21. Garofalo M, Moughan J, Hong T. RTOG 0822: a phase II study of preoperative chemoradiotherapy utilizing IMRT in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. IJ Radiat Oncol Biol Phys. 2011;81(2):S3–4. RTOG randomized study to elucidate impact in acute GI toxicity of IMRT in rectal cancer patients.

    Article  Google Scholar 

  22. Zhu J, Liu F, Gu W, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol. 2014;9:70–717X-9-70.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Hernando-Requejo O, Lopez M, Cubillo A, et al. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol. 2014;190(6):515–20.

    Article  PubMed  Google Scholar 

  24. Galvin JM, Ezzell G, Eisbrauch A, et al. Implementing IMRT in clinical practice: a joint document of the American society for therapeutic radiology and oncology and the American association of physicists in medicine. Int J Radiat Oncol, Biol, Phys. 2004;58(5):1616–34.

    Article  Google Scholar 

  25. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol, Biol, Phys. 2009;74(3):824–30.

    Article  Google Scholar 

  26. Nijkamp J, Marijnen C, van Herk M, van Triest B, Sonke JJ. Adaptive radiotherapy for long course neo-adjuvant treatment of rectal cancer. Radiother Oncol. 2012;103(3):353–9.

    Article  PubMed  Google Scholar 

  27. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-prodige 2. J Clin Oncol. 2010;28(10):1638–44.

    Article  CAS  PubMed  Google Scholar 

  28. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.

    Article  CAS  PubMed  Google Scholar 

  29. Rodel C, Hofheinz R, Liersch T. Rectal cancer: state of the art in 2012. Curr Opin Oncol. 2012;24(4):441–7.

    Article  PubMed  Google Scholar 

  30. Suwinski R, Taylor JM, Withers HR. Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Int J Radiat Oncol, Biol, Phys. 1998;42(5):943–51.

    Article  CAS  Google Scholar 

  31. Burbach JP, Verkooijen HM, Intven M, et al. RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): Study protocol for a randomized controlled trial. Trials. 2015;16(1):58. -015-0586-4.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Gerard JP, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol. 2004;22(12):2404–9.

    Article  PubMed  Google Scholar 

  33. Kim DY, Kim TH, Jung KH, et al. Preoperative chemoradiotherapy with concomitant small field boost irradiation for locally advanced rectal cancer: a multi-institutional phase II study (KROG 04-01). Dis Colon Rectum. 2006;49(11):1684–91.

    Article  PubMed  Google Scholar 

  34. Lee JH, Kim DY, Nam TK, et al. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01). Int J Radiat Oncol, Biol, Phys. 2012;84(4):955–61.

    Article  Google Scholar 

  35. Yeo SG, Oh JH, Kim DY, et al. Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). Int J Radiat Oncol, Biol, Phys. 2013;86(1):34–9.

    Article  CAS  Google Scholar 

  36. Engels B, Platteaux N, Van den Begin R, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol. 2014;110(1):155–9.

    Article  PubMed  Google Scholar 

  37. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol, Biol, Phys. 2003;56(1):83–8.

    Article  Google Scholar 

  38. McDonald MW, Godette KD, Butker EK, Davis LW, Johnstone PA. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis. Int J Radiat Oncol, Biol, Phys. 2008;72(4):1031–40.

    Article  Google Scholar 

  39. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176(4 Pt 1):1415–9.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Oncology, Clínica Universitaria de Navarra, University of Navarre, Avda Pío XII s/n., Pamplona, Navarre, Spain

    Leire Arbea & Javier Aristu

Authors
  1. Leire Arbea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Aristu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leire Arbea.

Additional information

This article is part of the Topical Collection on Localized Colorectal Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arbea, L., Aristu, J. The Role of Intensity-Modulated Radiotherapy to Optimize Outcomes in Locally Advanced Rectal Cancer. Curr Colorectal Cancer Rep 11, 345–351 (2015). https://doi.org/10.1007/s11888-015-0289-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-015-0289-y

Keywords

Search

Navigation